Redefining peptide therapeutics with semaglutide

Thomas Kruse and Søren Østergaard reflect on the development of the GLP-1 analogue, semaglutide, which is reshaping peptide therapeutics in type 2 diabetes, weight management, and beyond.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Nature chemistry 2024-02, Vol.16 (2), p.296-296
Hauptverfasser:	Kruse, Thomas, Østergaard, Søren
Format:	Artikel
Sprache:	eng
Schlagworte:	639/638/309/2144 639/638/92/611 Analytical Chemistry Antidiabetics Biochemistry Cardiovascular disease Chemistry Chemistry and Materials Science Chemistry/Food Science Diabetes Diabetes mellitus (non-insulin dependent) Drug dosages Fatty acids In Your Element Inorganic Chemistry Obesity Organic Chemistry Overweight Peptides Physical Chemistry Weight control
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Thomas Kruse and Søren Østergaard reflect on the development of the GLP-1 analogue, semaglutide, which is reshaping peptide therapeutics in type 2 diabetes, weight management, and beyond.
ISSN:	1755-4330 1755-4349
DOI:	10.1038/s41557-023-01434-4